Teladoc Health Financials

Teladoc Health Inc

TDOCNYSE

Trade with Public

$5.73

0.061.06%

마지막 업데이트: Oct 19, 5:19 PM

$5.75

0.08171.44%

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

실적: Q3 2026 실적이 수 10월 28th에 시장 마감 후 8일 후 후에 발표됩니다.

Teladoc Health Financials

Teladoc Health (TDOC) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Why Teladoc Stock is Getting Crushed Wednesday After Hours

Teladoc stock is sinking Wednesday after the company reported Q2 results and updated guidance. Here are the key figures to know.

Chris Katje

PRO
Teladoc Health Sees Q3 GAAP EPS $(0.30)-$(0.20) vs $(0.18) Est; Sees Sales $569.000M-$609.000M vs $629.252M Est

Teladoc Health (NYSE:TDOC) is looking for Q3 GAAP EPS of $(0.30)-$(0.20) vs $(0.18) analyst estimate. sees sales of $569.000 million-$609.000 million vs $629.252 million analyst estimate.

Benzinga Newsdesk

PRO
Teladoc Health Raises FY2026 GAAP EPS Guidance from $(1.05)-$(0.75) to $(1.00)-$(0.75) vs $(0.92) Est; Lowers FY2026 Sales Guidance from $2.481B-$2.576B to $2.362B-$2.447B vs $2.508B Est

Teladoc Health (NYSE:TDOC) raises FY2026 GAAP EPS guidance from $(1.05)-$(0.75) to $(1.00)-$(0.75) vs $(0.92) analyst estimate. Lowers FY2026 sales outlook from $2.481 billion-$2.576 billion to $2.362 billion-$2.447

Benzinga Newsdesk

PRO
Teladoc Health Q2 EPS $(0.21) Beats $(0.25) Estimate, Sales $606.927M Miss $615.391M Estimate

Teladoc Health (NYSE:TDOC) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.25) by 16 percent. This is a 10.53 percent decrease over losses of $(0.19) per share from the

Benzinga Newsdesk

Teladoc Shares Fall After Q1 Earnings: What Investors Need To know

Teladoc stock is trading lower after reporting first-quarter financial results. Here are the highlights.

Chris Katje

PRO
Teladoc Health Narrows FY2026 GAAP EPS Guidance from $(1.10)-$(0.70) to $(1.05)-$(0.75) vs $(0.89) Est; Narrows FY2026 Sales Guidance from $2.470B-$2.587B to $2.481B-$2.576B vs $2.509B Est.

Teladoc Health (NYSE:TDOC) narrows FY2026 GAAP EPS guidance from $(1.10)-$(0.70) to $(1.05)-$(0.75) vs $(0.89) analyst estimate. Narrows FY2026 sales outlook from $2.470 billion-$2.587 billion to $2.481 billion-$2.576

Benzinga Newsdesk

Teladoc Health Inc

Teladoc Health Financials

Earnings & Guidance News

Why Teladoc Stock is Getting Crushed Wednesday After Hours

PRO
Teladoc Health Sees Q3 GAAP EPS $(0.30)-$(0.20) vs $(0.18) Est; Sees Sales $569.000M-$609.000M vs $629.252M Est

PRO
Teladoc Health Raises FY2026 GAAP EPS Guidance from $(1.05)-$(0.75) to $(1.00)-$(0.75) vs $(0.92) Est; Lowers FY2026 Sales Guidance from $2.481B-$2.576B to $2.362B-$2.447B vs $2.508B Est

PRO
Teladoc Health Q2 EPS $(0.21) Beats $(0.25) Estimate, Sales $606.927M Miss $615.391M Estimate

Teladoc Shares Fall After Q1 Earnings: What Investors Need To know

PRO
Teladoc Health Narrows FY2026 GAAP EPS Guidance from $(1.10)-$(0.70) to $(1.05)-$(0.75) vs $(0.89) Est; Narrows FY2026 Sales Guidance from $2.470B-$2.587B to $2.481B-$2.576B vs $2.509B Est.

뉴스

파트너 / 기고자

벤징가 글로벌

Teladoc Health Financials

Earnings & Guidance News

Why Teladoc Stock is Getting Crushed Wednesday After Hours

PRO
Teladoc Health Sees Q3 GAAP EPS $(0.30)-$(0.20) vs $(0.18) Est; Sees Sales $569.000M-$609.000M vs $629.252M Est

PRO
Teladoc Health Raises FY2026 GAAP EPS Guidance from $(1.05)-$(0.75) to $(1.00)-$(0.75) vs $(0.92) Est; Lowers FY2026 Sales Guidance from $2.481B-$2.576B to $2.362B-$2.447B vs $2.508B Est

PRO
Teladoc Health Q2 EPS $(0.21) Beats $(0.25) Estimate, Sales $606.927M Miss $615.391M Estimate

Teladoc Shares Fall After Q1 Earnings: What Investors Need To know

PRO
Teladoc Health Narrows FY2026 GAAP EPS Guidance from $(1.10)-$(0.70) to $(1.05)-$(0.75) vs $(0.89) Est; Narrows FY2026 Sales Guidance from $2.470B-$2.587B to $2.481B-$2.576B vs $2.509B Est.

Teladoc Health Inc

Teladoc Health Financials

Earnings & Guidance News

Why Teladoc Stock is Getting Crushed Wednesday After Hours

PROTeladoc Health Sees Q3 GAAP EPS $(0.30)-$(0.20) vs $(0.18) Est; Sees Sales $569.000M-$609.000M vs $629.252M Est

PROTeladoc Health Raises FY2026 GAAP EPS Guidance from $(1.05)-$(0.75) to $(1.00)-$(0.75) vs $(0.92) Est; Lowers FY2026 Sales Guidance from $2.481B-$2.576B to $2.362B-$2.447B vs $2.508B Est

PROTeladoc Health Q2 EPS $(0.21) Beats $(0.25) Estimate, Sales $606.927M Miss $615.391M Estimate

Teladoc Shares Fall After Q1 Earnings: What Investors Need To know

PROTeladoc Health Narrows FY2026 GAAP EPS Guidance from $(1.10)-$(0.70) to $(1.05)-$(0.75) vs $(0.89) Est; Narrows FY2026 Sales Guidance from $2.470B-$2.587B to $2.481B-$2.576B vs $2.509B Est.

뉴스

파트너 / 기고자

벤징가 글로벌

Teladoc Health Financials

Earnings & Guidance News

Why Teladoc Stock is Getting Crushed Wednesday After Hours

PROTeladoc Health Sees Q3 GAAP EPS $(0.30)-$(0.20) vs $(0.18) Est; Sees Sales $569.000M-$609.000M vs $629.252M Est

PROTeladoc Health Raises FY2026 GAAP EPS Guidance from $(1.05)-$(0.75) to $(1.00)-$(0.75) vs $(0.92) Est; Lowers FY2026 Sales Guidance from $2.481B-$2.576B to $2.362B-$2.447B vs $2.508B Est

PROTeladoc Health Q2 EPS $(0.21) Beats $(0.25) Estimate, Sales $606.927M Miss $615.391M Estimate

Teladoc Shares Fall After Q1 Earnings: What Investors Need To know

PROTeladoc Health Narrows FY2026 GAAP EPS Guidance from $(1.10)-$(0.70) to $(1.05)-$(0.75) vs $(0.89) Est; Narrows FY2026 Sales Guidance from $2.470B-$2.587B to $2.481B-$2.576B vs $2.509B Est.

PRO
Teladoc Health Sees Q3 GAAP EPS $(0.30)-$(0.20) vs $(0.18) Est; Sees Sales $569.000M-$609.000M vs $629.252M Est

PRO
Teladoc Health Raises FY2026 GAAP EPS Guidance from $(1.05)-$(0.75) to $(1.00)-$(0.75) vs $(0.92) Est; Lowers FY2026 Sales Guidance from $2.481B-$2.576B to $2.362B-$2.447B vs $2.508B Est

PRO
Teladoc Health Q2 EPS $(0.21) Beats $(0.25) Estimate, Sales $606.927M Miss $615.391M Estimate

PRO
Teladoc Health Narrows FY2026 GAAP EPS Guidance from $(1.10)-$(0.70) to $(1.05)-$(0.75) vs $(0.89) Est; Narrows FY2026 Sales Guidance from $2.470B-$2.587B to $2.481B-$2.576B vs $2.509B Est.

PRO
Teladoc Health Sees Q3 GAAP EPS $(0.30)-$(0.20) vs $(0.18) Est; Sees Sales $569.000M-$609.000M vs $629.252M Est

PRO
Teladoc Health Raises FY2026 GAAP EPS Guidance from $(1.05)-$(0.75) to $(1.00)-$(0.75) vs $(0.92) Est; Lowers FY2026 Sales Guidance from $2.481B-$2.576B to $2.362B-$2.447B vs $2.508B Est

PRO
Teladoc Health Q2 EPS $(0.21) Beats $(0.25) Estimate, Sales $606.927M Miss $615.391M Estimate

PRO
Teladoc Health Narrows FY2026 GAAP EPS Guidance from $(1.10)-$(0.70) to $(1.05)-$(0.75) vs $(0.89) Est; Narrows FY2026 Sales Guidance from $2.470B-$2.587B to $2.481B-$2.576B vs $2.509B Est.